Cardiovascular risk in patients with severe mental illness in Italy.


Journal

European psychiatry : the journal of the Association of European Psychiatrists
ISSN: 1778-3585
Titre abrégé: Eur Psychiatry
Pays: England
ID NLM: 9111820

Informations de publication

Date de publication:
26 10 2020
Historique:
pubmed: 27 10 2020
medline: 1 5 2021
entrez: 26 10 2020
Statut: epublish

Résumé

Patients with severe mental illness (SMI), such as schizophrenia or bipolar disorders, are more frequently affected by metabolic syndrome and cardiovascular (CV) diseases than the general population, with a significant reduction in life expectancy. Beyond metabolic syndrome, quantifying the risk of CV morbidity in the long-term may help clinicians to put in place preventive strategies. In this study, we assessed 10-year CV risk in patients with SMI and healthy individuals using an algorithm validated on the Italian general population. Patients aged 35-69 years diagnosed with SMI were consecutively recruited from psychiatric acute care units. Single CV risk factors were assessed, and 10-year CV risk calculated by means of the CUORE Project 10-year CV risk algorithm, based on the combination of the following risk factors: age, systolic blood pressure, total and high-density lipoprotein cholesterol, diabetes, smoking habit, and hypertensive treatment. Patients' data were compared with those from the general population. The 10-year CV risk was log-transformed, and multivariable linear regression was used to estimate mean ratios, adjusting for age, and education. Three hundred patients and 3,052 controls were included in the analysis. Among men, the 10-year CV risk score was very similar between patients with SMI and the general population (mean ratio [MR]: 1.02; 95%CI 0.77-1.37), whereas a 39% increase in 10-year CV risk was observed in women with SMI compared to the general population (MR: 1.39; 95%CI 1.16-1.66). In our study, women with SMI were consistently more at risk than the general population counterpart, even at younger age.

Sections du résumé

BACKGROUND
Patients with severe mental illness (SMI), such as schizophrenia or bipolar disorders, are more frequently affected by metabolic syndrome and cardiovascular (CV) diseases than the general population, with a significant reduction in life expectancy. Beyond metabolic syndrome, quantifying the risk of CV morbidity in the long-term may help clinicians to put in place preventive strategies. In this study, we assessed 10-year CV risk in patients with SMI and healthy individuals using an algorithm validated on the Italian general population.
METHODS
Patients aged 35-69 years diagnosed with SMI were consecutively recruited from psychiatric acute care units. Single CV risk factors were assessed, and 10-year CV risk calculated by means of the CUORE Project 10-year CV risk algorithm, based on the combination of the following risk factors: age, systolic blood pressure, total and high-density lipoprotein cholesterol, diabetes, smoking habit, and hypertensive treatment. Patients' data were compared with those from the general population. The 10-year CV risk was log-transformed, and multivariable linear regression was used to estimate mean ratios, adjusting for age, and education.
RESULTS
Three hundred patients and 3,052 controls were included in the analysis. Among men, the 10-year CV risk score was very similar between patients with SMI and the general population (mean ratio [MR]: 1.02; 95%CI 0.77-1.37), whereas a 39% increase in 10-year CV risk was observed in women with SMI compared to the general population (MR: 1.39; 95%CI 1.16-1.66).
CONCLUSIONS
In our study, women with SMI were consistently more at risk than the general population counterpart, even at younger age.

Identifiants

pubmed: 33100262
doi: 10.1192/j.eurpsy.2020.94
pii: S0924933820000942
pmc: PMC7681153
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e96

Références

World Psychiatry. 2017 Jun;16(2):163-180
pubmed: 28498599
Ann Ist Super Sanita. 2004;40(4):393-9
pubmed: 15815105
Gen Hosp Psychiatry. 2016 Nov - Dec;43:46-50
pubmed: 27796257
Int J Psychiatry Med. 2013;45(3):203-26
pubmed: 24066405
Eur J Prev Cardiol. 2015 Sep;22(2 Suppl):9-37
pubmed: 26195612
CNS Drugs. 2011 Aug;25(8):659-71
pubmed: 21790209
Psychosomatics. 2013 Jan-Feb;54(1):67-73
pubmed: 22664309
Gen Hosp Psychiatry. 2014 Nov-Dec;36(6):698-702
pubmed: 25217493
Expert Rev Neurother. 2017 Jul;17(7):667-681
pubmed: 28468528
BMC Med. 2019 Jun 13;17(1):109
pubmed: 31189462
Schizophr Res. 2007 Feb;90(1-3):162-73
pubmed: 17123783
Psychopharmacology (Berl). 2016 Jan;233(1):49-56
pubmed: 26407602
World Psychiatry. 2015 Oct;14(3):339-47
pubmed: 26407790
Aust N Z J Psychiatry. 2019 Jul;53(7):651-662
pubmed: 30518229
Can J Cardiol. 2018 Apr;34(4):450-457
pubmed: 29571426
Psychiatry Clin Neurosci. 2011 Feb;65(1):47-54
pubmed: 21265935
JAMA Psychiatry. 2013 Sep;70(9):931-9
pubmed: 23863861
Cochrane Database Syst Rev. 2015 Aug 27;(8):CD011054
pubmed: 26310586
BJPsych Open. 2018 Jul 25;4(4):313-316
pubmed: 30083385
Expert Opin Drug Saf. 2015 Jan;14(1):73-96
pubmed: 25400109
Eur J Clin Pharmacol. 2018 Nov;74(11):1485-1489
pubmed: 30083876
Climacteric. 2012 Jun;15(3):229-34
pubmed: 22612608
Br J Psychiatry. 2020 Aug;217(2):442-449
pubmed: 31753047
Br J Psychiatry. 2003 Dec;183:534-9
pubmed: 14645025
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
Eur Psychiatry. 2018 Oct;54:124-144
pubmed: 30257806
Schizophr Res. 2005 Dec 1;80(1):45-53
pubmed: 16198088
JAMA Psychiatry. 2015 Feb;72(2):143-51
pubmed: 25536289
Front Psychiatry. 2018 Jun 07;9:235
pubmed: 29930520
Schizophr Res. 2013 Jun;147(1):187-192
pubmed: 23590873
Can J Psychiatry. 2004 Nov;49(11):753-60
pubmed: 15633853
Psychiatry Res. 2018 Jun;264:322-326
pubmed: 29665562

Auteurs

Virginio Salvi (V)

Department of Neuroscience, ASST Fatebenefratelli Sacco, Milan, Italy.

Andrea Aguglia (A)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Francesco Barone-Adesi (F)

Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.

Davide Bianchi (D)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Chiara Donfrancesco (C)

Department of Cardiovascular, Endocrine-metabolic Diseases and Aging, National Institute of Health, Rome, Italy.

Filippo Dragogna (F)

Department of Neuroscience, ASST Fatebenefratelli Sacco, Milan, Italy.

Luigi Palmieri (L)

Department of Cardiovascular, Endocrine-metabolic Diseases and Aging, National Institute of Health, Rome, Italy.

Gianluca Serafini (G)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Mario Amore (M)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Claudio Mencacci (C)

Department of Neuroscience, ASST Fatebenefratelli Sacco, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH